Episode 8 – Boston Scientific Outlook: Strong Fundamentals vs. Bearish TechnicalsBoston Scientific (BSX) just delivered a near-flawless fundamentals report card: a 67% gross profit margin, robust cash flow, and efficiency metrics that scream long-term strength. Yet Wall Street isn’t buying it. The technical picture is bearish, momentum looks weak, and money is flowing out from every investor group — institutions, block trades, and retail alike.In this episode, we explore the core contradiction:Why BSX scored an incredible 9.01 on fundamentals but just 3.0 on technicalsHow analysts remain divided, with average ratings bullish but performance-weighted ratings plungingThe surprising bearish history of “bullish engulfing” patterns for this stockWhy sector pressures, competition from Edwards Lifesciences, and AI-driven healthcare disruption matterThe practical advice: wait for a clearer trend or pullback before jumping inThis is more than one stock story — it’s a case study in how fundamentals and sentiment can diverge, leaving investors caught between value and momentum.⚠️ Disclaimer: This episode is for informational and educational purposes only and should not be considered financial or investment advice. Always do your own research or consult a licensed financial advisor before making decisions.

Ver todos los episodios